RT Journal Article
T1 An Early Th1 Response Is a Key Factor for a Favorable COVID-19 Evolution
A1 Gil Etayo, Francisco Javier
A1 Garcinuño, Sara
A1 Utrero Rico, Alberto
A1 Cabrera Marante, Oscar
A1 Arroyo Sánchez, Daniel
A1 Mancebo, Esther
A1 Pleguezuelo, Daniel Enrique
A1 Rodríguez Frías, Edgard
A1 Allende Martínez, Luis Miguel
A1 Morales Pérez, Pablo
A1 Castro Panete, María José
A1 Lalueza Blanco, Antonio
A1 Lumbreras Bermejo, Carlos Juan
A1 Paz Artal, Estela Natividad
A1 Serrano, Antonio
AB The Th1/Th2 balance plays a crucial role in the progression of different pathologies and is a determining factor in the evolution of infectious diseases. This work has aimed to evaluate the early, or on diagnosis, T-cell compartment response, T-helper subsets and anti-SARS-CoV-2 antibody specificity in COVID-19 patients and to classify them according to evolution based on infection severity. A unicenter, randomized group of 146 COVID-19 patients was divided into four groups in accordance with the most critical events during the course of disease. The immunophenotype and T-helper subsets were analyzed by flow cytometry. Asymptomatic SARS-CoV-2 infected individuals showed a potent and robust Th1 immunity, with a lower Th17 and less activated T-cells at the time of sample acquisition compared not only with symptomatic patients, but also with healthy controls. Conversely, severe COVID-19 patients presented with Th17-skewed immunity, fewer Th1 responses and more activated T-cells. The multivariate analysis of the immunological and inflammatory parameters, together with the comorbidities, showed that the Th1 response was an independent protective factor for the prevention of hospitalization (OR 0.17, 95% CI 0.03–0.81), with an AUC of 0.844. Likewise, the Th1 response was found to be an independent protective factor for severe forms of the disease (OR 0.09, 95% CI: 0.01–0.63, p = 0.015, AUC: 0.873). In conclusion, a predominant Th1 immune response in the acute phase of the SARS-CoV-2 infection could be used as a tool to identify patients who might have a good disease evolution.
PB MPDI
SN 2227-9059
YR 2022
FD 2022-01-27
LK https://hdl.handle.net/20.500.14352/71608
UL https://hdl.handle.net/20.500.14352/71608
LA eng
NO Instituto de Salud Carlos III (ISCIII) / FEDER
NO Fundación Mutua Madrileña
DS Docta Complutense
RD 8 abr 2025